|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0130 AUD | -7.14% |
|
-13.33% | -13.33% |
| 28/05 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 27/05 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 66.72L 45.91L 40.2L 37.11L 34.66L 65.24L 43Cr 4.47Cr 1.72Cr 21Cr 1.72Cr 1.69Cr 74Cr | P/E 2024 |
-3.44x | P/E 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 94.44L 64.99L 56.9L 52.53L 49.05L 92.34L 61Cr 6.32Cr 2.44Cr 30Cr 2.44Cr 2.39Cr 105.24Cr | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/22/23 | Acrux : Application for quotation of securities - ACR | PU |
| 14/22/14 | Acrux : Application for quotation of securities - ACR | PU |
| 16/22/16 | Acrux : Application for quotation of securities - ACR | PU |
| 25/22/25 | Acrux : Updated Board Charter | PU |
| 25/22/25 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | -7.14% | ||
| 1 week | -13.33% | ||
| Current month | +8.33% | ||
| 3 months | +8.33% | ||
| 6 months | -13.33% | ||
| Current year | -13.33% |
| 1 week | 0.01 | 0.02 | |
| 1 month | 0.01 | 0.02 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.14 | |
| 10 years | 0.01 | 0.84 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 01/06/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 15/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 01/01/2006 |
Timothy Oldham
BRD | Director/Board Member | - | 01/10/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 01/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.14% | -13.33% | -23.53% | -69.05% | 49.61L | ||
| +0.64% | +1.99% | +11.09% | +83.48% | 4.74TCr | ||
| +0.79% | +3.76% | +53.94% | +103.77% | 3.55TCr | ||
| +0.97% | +7.57% | -3.21% | +43.98% | 1.23TCr | ||
| +1.81% | +4.72% | +14.21% | +92.51% | 1.16TCr | ||
| -2.10% | +0.38% | +36.72% | +126.29% | 888.1Cr | ||
| -1.55% | +1.77% | +20.70% | +42.00% | 720.73Cr | ||
| +1.37% | +7.16% | +55.99% | -9.35% | 691.07Cr | ||
| +1.49% | -1.22% | +27.78% | +223.65% | 644.5Cr | ||
| +9.12% | +8.29% | -29.64% | +5.21% | 494.11Cr | ||
| Average | +0.54% | +2.51% | +16.40% | +64.25% | 1.41TCr | |
| Weighted average by Cap. | +0.89% | +3.14% | +24.50% | +85.56% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 50.91L 35.03L 30.67L 28.32L 26.44L 49.78L 33Cr 3.41Cr 1.32Cr 16Cr 1.32Cr 1.29Cr 57Cr | 11.9L 8L 7L 7L 6L 11.63L 7.74Cr 79.65L 30.75L 3.82Cr 30.75L 30.08L 13Cr |
| Net income | -58L -39.91L -34.94L -32.26L -30.12L -56.71L -38Cr -3.88Cr -1.5Cr -19Cr -1.5Cr -1.47Cr -65Cr | -59.45L -40.91L -35.82L -33.07L -30.88L -58.13L -39Cr -3.98Cr -1.54Cr -19Cr -1.54Cr -1.5Cr -66Cr |
| Net Debt | 8L 5L 5L 4L 4L 7L 4.94Cr 50.8L 19.61L 2.44Cr 19.61L 19.18L 8.46Cr | 27.72L 19.07L 16.7L 15.42L 14.4L 27.1L 18Cr 1.86Cr 71.63L 8.9Cr 71.63L 70.06L 31Cr |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/26/29 | A$0.0130 | -7.14% | 2,37,052 |
| 26/26/26 | A$0.0140 | +7.69% | 7,89,030 |
| 25/26/25 | A$0.0130 | -7.14% | 13,27,517 |
| 24/26/24 | A$0.0140 | +7.69% | 3,69,855 |
| 23/26/23 | A$0.0130 | -7.14% | 22,04,776 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















